Evan Lebois
About Evan Lebois
Evan Lebois is a Group Leader and Senior Research Scientist at the Broad Institute of MIT and Harvard, specializing in neuroimmunology and drug development for neurodegenerative diseases. He has an extensive academic background with degrees in Neuropharmacology, Medicinal Chemistry, and Neuroscience, and has held various research positions at notable institutions including Pfizer and Vanderbilt University.
Current Role at Broad Institute
Evan Lebois serves as a Group Leader and Senior Research Scientist at the Broad Institute of MIT and Harvard. He has held this position since 2018, contributing to the institute's research initiatives. His work focuses on applying systems biology approaches to neuroimmunology target validation, utilizing techniques such as single cell and bulk RNA sequencing, lipidomics, and proteomics. He designs and executes high-throughput screening assays to advance drug development for neurodegenerative diseases.
Previous Experience at Pfizer
Evan Lebois worked at Pfizer in two roles. From 2014 to 2018, he was a Senior Scientist in the Neuroscience Research Unit, where he focused on drug development strategies. Prior to that, he held a position in Business Development and Neuroscience Alliance Management for one year in 2017 to 2018. Both roles were based in Cambridge, MA, and contributed to his expertise in the pharmaceutical industry.
Educational Background
Evan Lebois has a comprehensive educational background in the life sciences. He earned a Doctor of Philosophy (Ph.D.) in Neuroscience from Emory University from 2010 to 2014. Prior to that, he obtained a Master's Degree in Neuropharmacology and Medicinal Chemistry from Vanderbilt University from 2007 to 2010. He also holds multiple Bachelor's Degrees in Chemistry, Biology (Cell/Molecular Biology/Genetics concentration), and Biochemistry from the University of Delaware, where he studied from 2003 to 2007.
Research Expertise and Contributions
Evan Lebois possesses extensive expertise in neuroimmunology and drug development, particularly in validating and drugging novel microglial targets for neurodegenerative diseases. He has over three years of experience in this area and applies his knowledge of microglia culture systems, functional and morphological assays. His research spans cross-species expertise, including studies involving flies, rodents, primates, and humans, and he has experience in back-translation of human biology to animal systems.
Collaboration and Networking
Evan Lebois has led complex external collaborations and academic-industry consortia throughout his career. He has developed a deep network of decision-makers across industry, academia, and investing communities. His passion lies in critically reviewing and interpreting published literature to guide strategic decisions in drug development, particularly for addressing unmet medical needs in brain disease.